Neuroendocrine Neoplasms
📧 Sign up to get email alerts when something new happens for Neuroendocrine Neoplasms.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma [Phase 2]
A Phase 2 clinical trial evaluating Lutathera (Lutetium-177 DOTATATE) for inoperable pheochromocytoma and paraganglioma is currently recruit…
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers [Phase 2]
A Phase 2 study (DAREON-5) is evaluating different doses of BI-764532 in people with small cell lung cancer and other neuroendocrine cancers…
-
CLINICAL_TRIALS research · 2025-12-12Clinical Trial Update: Clinical Study of Adjuvant Surufatinib Therapy for Postoperative High-risk Neuroendocrine Tumors Based on the Ninth Edition of the AJCC Staging System [Phase 2]
Phase 2 clinical trial evaluating adjuvant surufatinib for postoperative high-risk neuroendocrine neoplasms under the AJCC 9th edition stagi…
-
CLINICAL_TRIALS research · 2025-09-22Clinical Trial Update: PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial) [Phase 3]
Phase 3 trial PReCedeNT comparing PRRT alone versus PRRT with chemotherapy for gastroenteropancreatic neuroendocrine tumors is currently rec…
-
CLINICAL_TRIALS research · 2024-08-07Clinical Trial Update: Collection of Liquid Biopsy Samples of Neuroendocrine Neoplasms (NEN) Patients - Collection of NET (CollectNET) 2.0, a Study by the BE-FORCE Consortium
CollectNET 2.0 is a BE-FORCE consortium study recruiting neuroendocrine neoplasm patients to collect liquid biopsy samples. The trial is cur…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2018-04-30Clinical Trial Update: A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating 18F-AlF-NOTA-octreotide as a PET/CT imaging tracer for neuroendocrine neoplasms.